Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

Completed · Not applicable · Has a placebo group

Conditions studied: Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome

In brief

The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[SGLT2\].

Key facts

Study ID

NCT01439854

Run by

The University of Texas Health Science Center at San Antonio

People needed

18

Starts

2011-03-01

Expected to finish

2018-06-30

Last updated by the study team

2025-07-03

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• T2DM
• Drug Naive Or On Oral Therapy

You may not qualify if…

• Insulin Treatment
• Major Organ Disease

Where it is running

• Diabetes Division, UTHSCSA — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.